The abstract is read at the publisher; the summary is JClub's.
In early and advanced metabolic dysfunction-associated steatotic liver disease, platelets show heightened metabolic activity and altered reactivity, including oxPAPC-linked mitochondrial reprogramming.
- Why it matters: Platelet drivers in MASLD are poorly defined despite links to cardiovascular disease and accumulating oxidized phospholipids, limiting targeted diagnostics and therapies.
- What they did: In a cross-sectional cohort (simple steatosis n=42, steatohepatitis n=28, metabolic dysfunction-associated cirrhosis n=16, controls n=23), platelet metabolism and function were measured by flow cytometry and Seahorse, with ELISA for oxidized low-density lipoprotein; Ldlr -/- mice on an Amylin Liver NASH diet were compared with E06-scFv/Ldlr -/- mice that neutralize oxidized phospholipids.
- The result: Advanced MASLD platelets were refractory to G-protein-coupled receptor stimulation but more responsive to GPVI, and dysfunction correlated with mitochondrial activity and oxidized low-density lipoprotein; oxPAPC recapitulated these changes ex vivo, while oxidized phospholipid neutralization partially mitigated diet-induced platelet dysfunction and reduced binding to liver macrophages.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.